The Effect of Dopamine on Diabetic Retinopathy

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

August 15, 2019

Study Completion Date

August 15, 2019

Conditions
Diabetes
Interventions
DRUG

Low Dose Sinemet CR

Sinemet CR (25 mg carbidopa/100 mg levodopa) will be taken by mouth twice daily for two weeks.

DRUG

High Dose Sinemet CR

Sinemet CR (50 mg carbidopa/200 mg levodopa) will be taken by mouth twice daily for two weeks.

DEVICE

RETeval Electroretinogram (ERG) Testing

ERG testing consists of sitting in the dark for 15 minutes. During the procedure, participants will have a single-use adhesive sensor strip placed on the skin near the eye. A hand-held device, called the RETeval, will be placed in front of the eye and a series of flashes and flickering lights presented. The light intensity level is typically not uncomfortable. When right eye imaging is complete, the procedure will be repeated on the left eye. Both eyes will be evaluated in less than 5 minutes for most participants. Electroretinogram (ERG) testing will be completed at baseline, day 1, week 2, and week 4.

OTHER

Contrast Sensitivity Testing

Contrast sensitivity testing consists of looking at a series of moving lines on a tablet device. The lines will change from white to grey to black. Participants will be asked to determine when they can no longer distinguish between the lines. Contrast sensitivity testing will be completed at baseline, day 1, week 2, and week 4.

OTHER

Visual Acuity Testing

Participants will be asked to look at an eye chart with letters or symbols that become smaller as they move from top to bottom of the chart. Visual acuity testing will be completed at baseline, day 1, week 2, and week 4.

Trial Locations (1)

30033

Atlanta VA Medical Center, Atlanta

All Listed Sponsors
lead

Emory University

OTHER

NCT02706977 - The Effect of Dopamine on Diabetic Retinopathy | Biotech Hunter | Biotech Hunter